Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.87
+0.0000
Volume:- -
Turnover:- -
Market Cap:14.02B
PE:-182.12
High:131.87
Open:131.87
Low:131.87
Close:131.87
Loading ...

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Yahoo Finance
·
23 Jan

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

Dow Jones
·
22 Jan

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook

Benzinga
·
22 Jan

RBC Downgrades Intra-Cellular Therapies to Sector Perform From Outperform on Proposed Sale to Johnson & Johnson

MT Newswires Live
·
22 Jan

Intra-Cellular Therapies Inc : RBC Cuts to Sector Perform From Outperform; Raises Target Price to $132 From $108

THOMSON REUTERS
·
22 Jan

Intra-Cellular Therapies (ITCI) was downgraded to a Hold Rating at RBC Capital

TIPRANKS
·
22 Jan

Why Johnson & Johnson (JNJ) Is the Best Soaps and Cleaning Materials Stock to Invest In

Insider Monkey
·
21 Jan

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally

Insider Monkey
·
20 Jan

Weekly Winners | Intra-Cellular Therapies Soars 33%; MicroStrategy Rallies 21%; SoFi Gains 17%; XPeng Jumps 16%

Tiger Newspress
·
19 Jan

U.S. Weekly Review: Stock Market Rises On Tame Inflation, Bank Earnings

Investor’s Business Daily
·
18 Jan

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

Zacks
·
18 Jan

Johnson & Johnson Q4 EPS, Revenue Estimates Nudged Higher, BofA Says

MT Newswires Live
·
18 Jan

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns

GuruFocus.com
·
16 Jan

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires Live
·
15 Jan

J&J’s Prime Rating at Risk Because of Intra-Cellular Acquisition

Bloomberg
·
15 Jan

Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global

MT Newswires Live
·
15 Jan

Why Intra-Cellular (ITCI) Led the Monday Upsurge?

Insider Monkey
·
14 Jan

ITCI Poised for Turnaround Amid Rising Mental Health Concerns

GuruFocus.com
·
14 Jan

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Zacks
·
14 Jan

BUZZ-Brokerages downgrade Intra-Cellular after J&J deal

Reuters
·
14 Jan